Optimal drugs for second-line treatment of patients with small-cell lung cancer
Authors:
- Antonio RossiARAntonio Rossi
- Paola Claudia SaccoPSPaola Claudia Sacco
- Assunta SgambatoASAssunta Sgambato
- Francesca CasaluceFCFrancesca Casaluce
- Giuseppe SantabarbaraGSGiuseppe Santabarbara
- Giovanni PalazzoloGPGiovanni Palazzolo
- Paolo MaionePMPaolo Maione
- Cesare GridelliCGCesare Gridelli
- 29 February 2016
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 17 (7) , 969-976
Abstract
Despite the high response rate to chemotherapy, there have been few advances in the treatment of small-cell lung cancer (SCLC) in the last decades. The state-of-the-art second-line therapy and future research developments in relapsed SCLC are reviewed. There are no optimal drugs for second-line treatment of recurrent SCLC but only agents registered for this use. Topotecan remains the standard-of-care for the treatment of second-line platinum-sensitive SCLC patients worldwide, while amrubicin is another option, but registered only in Japan. To date, no targeted agents reporting interesting results in second-line SCLC treatment are available. The next-generation DNA sequencing should discover somatic gene alterations and their roles in SCLC to help in selecting patients who could benefit from a targeted agent. Two immunotherapeutics, ipilimumab and nivolumab, have shown promising preliminary results and are being investigated in ongoing trials. Second-line treatment is not an option for most SCLC patients. Given the evidence up to now, the potentials for immuno-oncology in SCLC are high. The hope is that these expectations are met, and that all drugs being developed will offer new and improved treatment options for SCLC patients.Keywords
This publication has 46 references indexed in Scilit:
- Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumorsProceedings of the National Academy of Sciences, 2010
- A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancerLung Cancer, 2009
- A prospective phase II study: High-dose pemetrexed as second-line chemotherapy in small-cell lung cancerLung Cancer, 2009
- Novel insights into the differential functions of Notch ligands in vascular formationJournal of Angiogenesis Research, 2009
- Current Status of Second-Line Treatment and Novel Therapies for Small Cell Lung CancerJournal of Thoracic Oncology, 2007
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007
- Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancerLung Cancer, 2004
- Evaluation of high-dose etoposide combined with cisplatin for treating relapsed small cell lung cancerCancer, 1990
- Cisplatin and Etoposide as Second-Line Chemotherapy in Patients with Small Cell Lung CancerCancer Investigation, 1988
- VP-16 alone and in combination with cisplatin in previously treated patients with small cell lung cancerCancer, 1984